“Over the past 13 years, I had the greatest opportunity to exploit my passion for science at IPST by contributing to the design, and validation of unique assays which are now routinely run and serve to quantify the efficacy in preclinical drug candidates. My greatest contribution was to see the increase in demand for efficacy services such as the rodent model of pulmonary arterial hypertension (PAH), as well as our intravascular thrombosis and hemostasis models.” Charles completed his doctorate in Pharmacology at the Université de Montreal followed by 4 years of post doctorate studies at the University of Pittsburgh in the Department of Molecular Genetics and Biochemistry. His field of expertise includes cardiovascular pharmacology and molecular biology.
Connect with Charles-E. Laurent
Alcoholic Steatohepatitis (ASH)
Purpose
Alcoholic Steatohepatitis is a chronic, progressive liver disease characterized scarring (fibrosis) of the liver as well as death (necrosis) of the hepatocytes, brought on by excessive, prolonged alcohol use.
Method
The Lieber-DeCarli liquid diet model is widely used and studied to simulate human drinking and mimic the spectrum and severity of alcoholic fatty liver disease (AFLD). EtOH feeding causes hepatic steatosis with limited liver injury with increasing of hepatic oxidative stress and pro-inflammatory cytokine production.
Study outcome
Extensive liver histology analysis, Liver triglyceride content, Blood ALT and AST
Species
Mice
Charles-E. Laurent
Ph.D., Director of In-Vivo Pharmacology
